Table 2 Included papers, clinical trial/registry/patient population characteristics

1

Drug trial

General eligibility for lung cancer trials and studies

N/A

Cancer registry

Local (center specific)

Patients with lung cancer

Not specified

1

N/A

N/A

N/A

N/A

2

Drug trial

General eligibility for cancer trials

N/A

Cancer registry

Local (center specific)

Patients with cancer

≥ 30

N/A

N/A

N/A

N/A

N/A

3

Non-drug trial

IMPACT

NCT03569605

UNC Health Registry/Cancer Survivorship Cohort

Local (center specific)

Young adult cancer survivors (YACS)

18–39

101

N/A

N/A

N/A

3.60%

4

Non-drug trial

CONTROL-RA

N/A

ArthritisPower patient registry

National

Patients with rheumatoid arthritis

≥ 19

27,000

1254

234

0.87%

18.60%

5

Non-drug trial

EXERT

NCT02814526

National and local registries

Both national and local registries

Patients with mild cognitive impairment

65–89

N/A

N/A

N/A

N/A

N/A

6

Drug trial

16 trials

N/A

National ALS Registry

National

Patients with amyotrophic lateral sclerosis

≥ 18

7030

N/A

2000

28.40%

N/A

7

Drug trial

General eligibility for “for all available pancreatic cancer clinical trials”

N/A

Abramson Cancer Center cancer registry

Local (center specific)

Patients with pancreatic cancer

≥ 18

233

142

N/A

N/A

N/A

8

Drug trial

General eligibility for cancer trials

N/A

Duke Molecular Registry of Tumors

National

Patients with cancer

≥ 18

N/A

N/A

32

N/A

N/A

9

Non-drug trial

Effect evaluation of Oncokompas 2.0

N/A

Netherlands Cancer Registry

National

Patients with cancer

≥ 18

2953

N/A

625

21.20%

N/A

10

Drug trial

SHERBOC

NCT03241810

PRAEGNANT registry

National

Postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer

≥ 18

2769

125

N/A

N/A

N/A

11

Non-drug trial

TARGET-AC

NCT02520180

All comer disease registry

International

Patients with coronary artery disease

≥ 18

912

789

131

14.40%

16.60%

12

Non-drug trial

TASTE

NCT01093404

Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

National

Patients with a diagnosis of ST-segment elevation myocardial infarction

≥ 18

11,956

7259

7244

60%

99%

13

Non-drug trial

DYVINE

NCT01225614

DM-Scope registry

National

Patients with myotonic dystrophy

≥ 18

2648

N/A

N/A

N/A

N/A

14

Drug trial

Generic eligibility for “current” pediatric type 2 diabetes

N/A

Pediatric Diabetes Consortium T2D Registry

National

Pediatric patients with diabetes

10 to < 18 years

956

604

N/A

N/A

N/A

15

Drug trial

COMPASS

NCT01776424

Reduction of Atherothrombosis for Continued Health (REACH) registry

International

Coronary artery disease

Patients with coronary artery disease or peripheral artery disease

≥ 18

65,531

16,875

9126

14%

54%

16

Drug trial

6 trials

N/A

UK Primary Sjögren’s Syndrome Registry

National

Patients with Sjögren’s syndrome

Not specified

688

681

N/A

N/A

N/A

17

Non-drug trial

COURAGE

NCT02250053

Pennsylvania Cancer Registry

Local (Pennsylvania)

Patients who survived colon cancer

≥ 18

1435

1433

39

2.70%

2.70%

18

Non-drug trial

ASCEND

NCT00135226

Patient registry

National

Patients with diabetes

≥ 40

300,188

16,091

9013

3%

56%

19

Non-drug trial

COPD-SMART

NCT01108991

Patient registry

Local (Texas)

Patients with COPD

≥ 45

1666

924

325

19%

35%

20

Non-drug trial

DILT1D

NCT01827735

Patient registry

National

Patients with typ 1 Diabetes

18–50

477

59

10

2%

17%

21

Drug trial

OPTEX

NCT00803309

Patient registry

National

Patients with chronic HCV

≥ 18

1006

226

104

10%

46%

22

Drug trial

Effect of Alfacalcidol on multiple sclerosis-related fatigue

N/A

Patient registry

Local (center specific)

Patients with MS and fatigue

18–55

600

259

158

26%

61%

23

Drug trial

VERVE

NCT02538341

Consortium of Rheumatology Researchers of North America (CORRONA) disease registry

National

Patients with rheumatoid arthritis

≥ 50

50,000

12,000

Not indicated

N/A

N/A

24

Non-drug trial

Un-named trial

N/A

California Cancer Registry

Local and national

African American or Latino breast cancer survivors

≥ 18

529

252

221

42%

48%